VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AIMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
AIMDAinos, Inc.
$1.73$8M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksAIMDFinancials

Ainos, Inc. (AIMD) Financials

30Y historyFree accessUpdated daily

The company's commercial viability remains severely constrained, with gross margins plummeting to -7296.1% in 2026Q1 due to fixed overheads decoupled from negligible sales.

AIMD Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue18.11K124.16K20.73K122.11K3.52M594.56K16.56K11.73K77.72K250.93K01.98K0053058.4K5.15K52.25K109.84K70.07K133.94K154.56K51.51K99.59K79.73K703.89K53.76K2.4K222.29K652.66K668.79K
Revenue Growth %-82.95%498.95%-83.02%-96.53%491.97%3489.71%41.19%-84.91%-69.03%--100%---100%-99.09%1033.88%-90.14%-52.43%56.75%-47.69%-13.34%200.09%-48.28%24.92%-88.67%1209.42%2139.83%-98.92%-65.94%-2.41%-52.23%
Cost of Goods Sold4.78M4.8M52.59K375.85K2.11M184.18K11.28K8.77K64.88K60.32K25.96K19.77K002124.35K2.94K25.81K54.62K68025822.46K14.95K4.01K000-25.72K000
COGS % of Revenue-3867.2%253.73%307.79%60.07%30.98%68.09%74.78%83.47%24.04%-1001.11%--40%7.46%57.15%49.4%49.72%0.97%0.19%14.53%29.02%4.03%----1071.75%---
Gross Profit-4.76M-4.68M-31.87K-253.73K1.41M410.38K5.29K2.96K12.85K190.61K-25.96K-17.8K0031854.04K2.21K26.44K55.22K69.39K133.68K132.11K36.56K95.58K79.73K703.89K53.76K28.12K222.29K652.66K668.79K
Gross Margin %-26296.83%-3767.2%-153.73%-207.79%39.93%69.02%31.91%25.22%16.53%75.96%--901.11%--60%92.54%42.85%50.6%50.28%99.03%99.81%85.47%70.98%95.97%100%100%100%1171.75%100%100%100%
Gross Profit Growth %--14577.84%87.44%-118.05%242.45%7663.56%78.64%-76.97%-93.26%834.37%-45.84%---100%-99.41%2348.62%-91.65%-52.11%-20.42%-48.09%1.19%261.38%-61.75%19.88%-88.67%1209.42%91.15%-87.35%-65.94%-2.41%-52.23%
Operating Expenses8.35M9.31M13.81M12.95M15.38M4.28M1.45M1.58M1.35M770.38K667.11K521.8K566.15K566.15K554.93K1.2M1.07M1.67M1.89M2.49M2.82M680.47K533.43K568.12K686.51K1.09M3.37M6.21M2.44M3.01M2.16M
OpEx % of Revenue-7501.12%66618.45%10607.2%437.02%719.49%8728.62%13497.33%1733.73%307.01%-26420.05%--104703.02%2054.84%20806.23%3191.13%1722.55%3550.36%2107.72%440.25%1035.67%570.43%861.04%155.26%6262.25%258923.29%1096.81%460.56%323.11%
Selling, General & Admin1.82M1.56M5.4M5.64M8.54M2.36M1.45M1.53M1.31M770.38K667.11K521.8K433.19K433.19K355.33K918.81K638.16K1.2M1.37M1.96M2.29M492.66K362.39K394.77K303.63K576.57K1.09M1.46M1.07M1.36M1.52M
SG&A % of Revenue-1259.21%26028.34%4614.84%242.51%396.45%8726.27%13049.71%1691.8%307.01%-26420.05%--67042.83%1573.45%12391.53%2301.65%1243.74%2792.73%1708.24%318.74%703.58%396.38%380.82%81.91%2027.37%60669.67%479.21%207.68%226.76%
Research & Development6.53M7.75M8.41M7.32M6.85M1.92M38952.51K32.59K000132.96K132.96K199.6K281.11K433.36K464.79K525.9K530.87K535.08K187.81K171.04K173.34K382.88K516.29K2.28M4.73M1.37M1.65M644.37K
R&D % of Revenue-6241.91%40590.11%5992.36%194.51%323.03%2.35%447.62%41.93%-----37660.19%481.39%8414.7%889.48%478.81%757.63%399.48%121.51%332.08%174.05%480.22%73.35%4234.88%197181.88%617.6%252.88%96.35%
Other Operating Expenses10000000000000000000000000025.72K000
Operating Income-13.11M-13.99M-13.84M-13.21M-13.98M-3.87M-1.44M-1.58M-1.33M-579.76K-667.11K-519.82K-622.6K-566.15K-554.61K-1.15M-1.07M-1.64M-1.84M-2.42M-2.69M-548.36K-496.87K-472.53K-606.78K-388.97K-3.31M-6.19M-2.22M-2.35M-1.49M
Operating Margin %-72393.48%-11268.32%-66772.17%-10814.99%-397.09%-650.47%-8696.7%-13472.11%-1717.2%-231.05%--26320.05%---104643.02%-1962.29%-20763.38%-3140.52%-1672.27%-3451.34%-2007.91%-354.78%-964.69%-474.46%-761.04%-55.26%-6162.25%-257751.54%-996.81%-360.56%-223.11%
Operating Income Growth %--1.08%-4.81%5.51%-261.38%-168.49%8.86%-18.41%-130.21%13.09%-28.33%16.51%-9.97%-2.08%51.6%-7.16%34.84%10.66%24.05%10.08%-390.45%-10.36%-5.15%22.12%-56%88.26%46.45%-179.18%5.84%-57.71%-86.52%
EBITDA-8.33M-9.21M-9.04M-8.34M-9.16M-1.82M-1.43M-1.56M-1.28M-539.77K-641.15K-500.05K-605.06K-550.03K-539.04K-1.13M-1.05M-1.62M-1.82M-2.4M-2.67M-535.92K-467.83K-450.39K-583.95K-366.04K-3.29M-6.16M-2.19M-2.32M-1.47M
EBITDA Margin %-46017.5%-7418.23%-43607.93%-6825.98%-260.33%-306.61%-8607.96%-13282.52%-1644.9%-215.11%--25318.94%---101704.91%-1933.87%-20377.92%-3098.46%-1654.27%-3424.53%-1996.58%-346.73%-908.31%-452.22%-732.4%-52%-6117.65%-256679.79%-984.23%-356.11%-219.23%
EBITDA Growth %8.48%-1.89%-8.45%9.03%-402.61%-27.86%8.5%-21.88%-136.86%15.81%-28.22%17.36%-10%-2.04%52.27%-7.61%35.18%10.89%24.28%10.27%-399%-14.55%-3.87%22.87%-59.53%88.87%46.62%-181.57%5.87%-58.52%-4.73%
D&A (Non-Cash Add-back)4.78M4.78M4.8M4.87M4.81M2.04M14.7K22.24K56.19K39.99K25.96K19.77K17.54K16.12K15.57K16.6K19.85K21.98K19.77K18.78K15.18K12.44K29.04K22.14K22.83K22.93K23.98K25.72K27.96K29.04K25.97K
EBIT-13.11M-13.99M-14.25M-13.63M-13.95M-3.87M-1.44M-1.58M-1.33M-579.76K-667.11K-519.82K-469.03K-566.15K-495.29K-1.1M600.26K-1.64M-1.84M-2.42M-2.69M-548.36K-496.87K-472.53K-606.78K-388.97K-3.36M-6.19M-2.22M-2.35M-1.49M
Net Interest Income-708.33K-711.9K-616.47K-144.19K-53.53K-18.69K-10.19K-885-3.96K-37.61K00-1.89K0-155.56K-211.72K-93.95K-89.76K-86.31K-87.76K-90.11K-120.65K-98.33K-97.96K-97.31K-92.64K-35.81K0-117K0-126.06K
Interest Income000000000000000003.4K6.13K2.89K3.03K0001.74K2.34K47.02K0000
Interest Expense708.33K711.9K616.47K144.19K53.53K18.69K10.19K8853.96K37.61K2.87K2.05K1.89K103.37K155.56K211.72K93.95K93.16K92.44K90.65K93.15K120.65K98.33K97.96K99.05K94.98K82.82K0117K0126.06K
Other Income/Expense-832.81K-779.8K-1.02M-563.35K-30.48K-5.09K-10.19K-885-3.96K-37.61K-2.87K-2.05K3.42M-56.45K-96.24K-167.89K1.58M-1.33M-86.31K-87.76K-88.22K-120.65K-98.33K472.53K8.71K058.66K-5.74K-117K-118.06K-126.06K
Pretax Income-13.94M-14.77M-14.86M-13.77M-14.01M-3.87M-1.45M-1.58M-1.34M-617.38K-669.98K-521.87K-622.6K-622.6K-650.85K-1.31M506.31K-2.97M-1.92M-2.51M-2.78M-669.01K0314.88K-598.07K0-3.31M-6.19M-2.33M-2.47M-1.62M
Pretax Margin %-76991.83%-11896.4%-71698.4%-11276.33%-397.96%-651.32%-8758.21%-13479.65%-1722.3%-246.04%--26424%---122801.32%-2249.8%9831.3%-5686.09%-1750.85%-3576.58%-2073.78%-432.83%-316.17%-750.12%--6149.72%-257990.5%-1049.45%-378.64%-241.96%
Income Tax800800800800016.14K0000003.29M00000000098.33K-639.16K99.05K92.64K82.82K-67.45K000
Effective Tax Rate %-0.01%-0.01%-0.01%-0.01%0%-0.42%0%0%0%0%0%0%-528.62%0%0%0%0%0%0%0%0%0%--202.98%-16.56%--2.51%1.09%0%0%0%
Net Income-13.94M-14.77M-14.86M-13.77M-14.01M-3.89M-1.45M-1.58M-1.34M-617.38K-669.98K-521.87K-622.6K-622.6K-650.85K-1.31M506.31K-2.97M-1.92M-2.51M-2.78M-669.01K-595.21K166.63K-705.82K-481.61K-3.4M-6.12M-2.33M-2.47M-1.62M
Net Margin %-76996.25%-11897.04%-71702.26%-11276.98%-397.96%-654.04%-8758.21%-13487.2%-1722.3%-246.04%--26424%---122801.32%-2249.8%9831.3%-5686.09%-1750.85%-3576.58%-2073.78%-432.83%-1155.6%167.31%-885.27%-68.42%-6316.33%-254941.08%-1049.45%-378.64%-241.96%
Net Income Growth %6%0.62%-7.93%1.69%-260.19%-168.07%8.32%-18.19%-116.83%7.85%-28.38%16.18%0%4.34%50.46%-359.48%117.04%-54.5%23.26%9.78%-315.19%-12.4%-457.2%123.61%-46.56%85.82%44.51%-162.28%5.6%-52.72%-439.4%
Net Income (Continuing)-13.94M-14.77M-14.86M-13.77M-14.01M-3.89M-1.45M-1.58M-1.34M-617.38K-669.98K-521.87K2.84M-622.6K-650.85K-1.31M506.31K-2.97M-1.92M-2.51M-2.78M-669.01K-595.21K166.63K-705.82K-481.61K-3.4M-6.12M-2.33M-2.47M-1.62M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)-2.31-3.46-1.56-3.36-5.14-2.59-2.69-0.74-0.56-0.41-0.50-0.39-0.83-2.42-2.53-5.762.85-20.03-17.65-26.88-35.22-11.56-13.635.70-22.69-17.48-125.43-274.09-122.80-130.09-117.06
EPS Growth %98.61%-121.79%53.57%34.63%-98.46%3.72%-263.51%-32.14%-36.59%18%-28.21%53.01%65.7%4.35%56.08%-302.11%114.23%-13.48%34.34%23.68%-204.67%15.19%-339.12%125.12%-29.81%86.06%54.24%-123.2%5.6%-11.13%-310.74%
EPS (Basic)--3.46-1.56-3.36-5.14-2.59-2.69-0.74-0.56-0.41-0.50-0.39-0.83-2.42-2.53-5.762.85-20.03-17.65-26.88-35.22-11.56-13.635.70-22.69-17.48-125.43-274.09-122.80-130.09-117.06
Diluted Shares Outstanding6.03M4.27M9.5M4.1M2.73M1.51M543.08K2.15M2.38M1.51M1.34M1.34M746K257.7K257.43K228.17K199.61K148.34K108.94K93.23K78.88K57.88K43.67K34.39K31.1K27.55K27.07K22.32K19K19K13.82K
Basic Shares Outstanding6.03M4.27M9.5M4.1M2.73M1.51M543.08K2.15M2.38M1.51M1.34M1.34M746K257.7K257.43K228.17K193.13K148.34K108.94K93.23K78.88K57.88K43.67K34.39K31.1K27.55K27.07K22.32K19K19K13.82K
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity insolvency risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Base Lacks Commercial Scale

As reported in recent financial filings, Ainos generated a nominal $161 in revenue for 2026Q1, reflecting a near-total collapse from previous periods and underscoring the company's inability to establish a sustainable, recurring revenue stream across its diagnostic and synthetic RNA technology platforms in the current market environment.

The extreme volatility and negligible absolute revenue figures suggest that the company's top line is driven by sporadic, non-recurring contracts rather than a repeatable business model. Investors should monitor whether the pivot toward VOC sensing can generate meaningful commercial traction, as current data indicates the firm remains in a pre-revenue state.

Structural Negative Margins Persist Unabated

Based on the company's reported income statements, gross margins have remained deeply negative, reaching -7296.1% in 2026Q1, which suggests that the cost of goods sold is heavily burdened by fixed manufacturing overheads that are entirely decoupled from the firm's current, minimal sales volume.

This margin profile implies that the company is effectively subsidizing its production capacity without achieving the necessary scale to cover basic variable costs. Such structural inefficiency warrants further investigation into whether the current manufacturing strategy is viable or if it requires a fundamental shift to a lower-cost, outsourced model.

Operating Expenses Outpace Revenue Generation

According to quarterly data, Ainos continues to incur significant R&D expenditures, with $1.1 million reported in 2026Q1, which highlights a persistent reliance on high-burn operational spending despite the absence of a corresponding revenue base to support these ongoing clinical and technological development activities.

The company's cost structure appears to be prioritized toward long-term R&D at the expense of immediate financial stability. This strategy may indicate a management focus on achieving regulatory milestones, yet it leaves the firm highly exposed to capital market volatility given the lack of internal cash generation.

Capital Structure Risks Demand Scrutiny

As indicated by the provided financial statements, the company's operating losses consistently exceed its cash reserves, creating a precarious financial position that suggests the firm may be forced to pursue dilutive equity financing to maintain its ongoing research and development operations in the near term.

The disconnect between the company's ambitious technological goals and its limited liquidity profile suggests that the current trajectory may be unsustainable without a major strategic partnership or capital injection. Investors should remain cautious regarding the potential for significant shareholder dilution as the firm attempts to bridge its funding gap.

AIMD — Frequently Asked Questions

Quick answers to the most common questions about buying AIMD stock.

What was Ainos, Inc.'s (AIMD) revenue in 2025?

For fiscal year 2025, Ainos, Inc. (AIMD) reported total revenue of $0.1M. This represents a 81.4% decline compared to $0.7M in 1996.

Is Ainos, Inc. (AIMD) profitable?

Ainos, Inc. (AIMD) reported a net loss of $14.8M for the fiscal year ending 2025.

What is Ainos, Inc.'s operating profit margin?

Ainos, Inc. (AIMD) reported an operating income of $-14.0M, resulting in an operating profit margin of -11268.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Ainos, Inc.'s gross profit and gross margin?

Ainos, Inc. (AIMD) generated $-4.7M in gross profit for the year, representing a gross profit margin of -3767.2%. This demonstrates the company's core pricing power and production efficiency.